UnitedHealthcare
IDHIFA (enasidenib)
Drugs for Cancer : Drugs for Cancer
  • Prior Authorization: Acute Myeloid Leukemia:
    Documented Diagnosis: Yes
    Medical Test Required: Yes
    Duration: 12 Month(s)
    Reauthorization Required: Yes

  • Orally administered anticancer medication.
  • Acute Myeloid Leukemia:
    Duration: 12 Month(s)
    Documented Diagnosis: Yes
    Medical Test Required: Yes
    Reauthorization Required: Yes
    Duration of Reauthorization: = 12 month(s)
    Drug Policy Based On: 1 of FDA Approved Indications;NCCN Guidelines
    Quantity Limit: N/A
    Criteria for Reauthorization: No evidence of disease progression or unacceptable toxicity
    Use of Biomarkers in Policy: IDH2 mutation
    Diagnosis Types: 2 of >=60 years and not a candidate for intensive remission induction therapy;Acute myeloid leukemia;Medically accepted uses supported by NCCN Category 1, 2A or 2B level of evidence;Post Remission Therapy;Relapsed/Refractory acute myeloid leukemia
    Excludes Coverage in Maintenance Setting: No

  • Quantity Limit: limit maximum 1 EA PER 1 day(s)